Tacrolimus Anhydrous: Side Effects, Uses & Monitoring
Tacrolimus ointment, both 0.03% and 0.1% for adults, and only 0.03% for children aged 2 to 15 years, is indicated as second-line therapy for the short-term and non-continuous chronic treatment of moderate to severe atop
- Data source
- FDA labeling via NIH DailyMed (label 80e6817a…)
- Label version
- current
- Last reviewed
- 2026
Reported adverse reactions
Reactions listed in current FDA labeling, with the highest frequency reported across summarized placebo-controlled trials.
| Adverse reaction (as reported in labeling) | Reported frequency* |
|---|---|
| < 1 year | 9163% |
| ≥ 1 year | 2534% |
| ≥ 2 years | 475% |
| ≥ 3 years | 300% |
| Skin erythema | 28% |
| Fever | 21% |
| Cough increased | 18% |
| Skin infection | 16% |
| Allergic reaction | 13% |
| Asthma | 13% |
| Pharyngitis | 12% |
| Otitis media | 12% |
| Infection | 10% |
| Accidental injury | 8% |
| Pustular rash | 7% |
| Vomiting | 7% |
| Dry skin | 7% |
| Rhinitis | 6% |
| Urticaria | 6% |
| Lack of drug effect | 6% |
*Highest percentage reported for the active moiety across placebo-controlled trial tables in current FDA labeling. Values reflect trial reporting, not your individual risk.
Labeled uses (from FDA prescribing information)
Tacrolimus ointment, both 0.03% and 0.1% for adults, and only 0.03% for children aged 2 to 15 years, is indicated as second-line therapy for the short-term and non-continuous chronic treatment of moderate to severe atopic dermatitis in non-immunocompromised adults and children who have failed to respond adequately to other topical prescription treatments for atopic dermatitis, or when those treatments are not advisable. Tacrolimus ointment is not indicated for children younger than 2 years of age (see boxed WARNING , WARNINGS and PRECAUTIONS : Pediatric Use ).
Conditions associated with Tacrolimus Anhydrous in labeling
Frequently Asked Questions
What is Tacrolimus Anhydrous used for?
FDA labeling lists the approved uses shown above under "Labeled uses." This summary is informational; only a qualified prescriber can determine whether a medication is appropriate for you.
What are the most commonly reported side effects of Tacrolimus Anhydrous?
The table above shows adverse reactions and the highest frequencies reported in placebo-controlled trials summarized in current FDA labeling for Tacrolimus Anhydrous. Individual risk varies.
Does Tacrolimus Anhydrous require lab monitoring?
Monitoring needs vary. Ask your healthcare provider whether any lab tests apply while taking Tacrolimus Anhydrous.
Where does this information come from?
All clinical facts on this page were extracted from the current FDA-registered product labeling for this ingredient, published by manufacturers through NIH DailyMed. See the source link below.
Medical disclaimer: Educational content extracted from public FDA labeling. Not medical advice. Always consult a qualified healthcare professional before starting, stopping, or changing any medication.